Moderna combined its vaccine with Merck's Keytruda drug.
3 reports, 2 independent
Updated Sep 4
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Moderna combined its vaccine with Merck's Keytruda drug.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Moderna announced a collaboration with Merck KGaA regarding a personalized cancer vaccine platform.Also in this story
- Moderna and Merck KGaA are working on personalized melanoma shots, with manufacturing challenges being discussed by Amy Walker.
- Moderna and Merck developed personalized mRNA cancer vaccine Intismeran following trial success, leading to a surge in Moderna's shares.
- Moderna and Merck developed a new therapy.
- Moderna, Merck, and the National Cancer Institute announced successful trial results for a combined cancer vaccine and immunotherapy program.
The entities involved
Related events
- Moderna, Pfizer, and Merck are part of a healthcare rotation story, with Moderna outperforming Pfizer in current stock gains.
- Nasdaq added Moderna to its Nasdaq-100 index, and Moderna combined its vaccine with Merck's drug.
- Moderna's therapy combined with Merck's drug in an Australian-led clinical trial.
- Uğur Şahin and Özlem Türeci plan to leave BioNTech, while Moderna and Merck advance their combined vaccine study.